We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

73 hedge funds and large institutions have $905M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

18% more funds holding

Funds holding: 62 → 73 (+11)

2% more capital invested

Capital invested by funds: $891M → $905M (+$14.4M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+11
Holders Change %
+17.74%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
17
Increased
32
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$17M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.6M
3
BlackRock
BlackRock
New York
+$13.1M
4
Morgan Stanley
Morgan Stanley
New York
+$6.88M
5
NHAS
Novo Holdings A/S
Denmark
+$4.32M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$26.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$10.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$10.4M
4
Franklin Resources
Franklin Resources
California
-$4.47M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$223M – – –
O
2
OrbiMed
New York
$88.6M – – –
RCM
3
RA Capital Management
Massachusetts
$82.7M – – –
VVA
4
Vida Ventures Advisors
Massachusetts
$63.2M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$48.3M -$167K -7,675 -0.4%
BlackRock
6
BlackRock
New York
$43.1M +$13.1M +600,832 +47%
Vanguard Group
7
Vanguard Group
Pennsylvania
$42.9M +$14.6M +672,778 +57%
BC
8
Boxer Capital
California
$42.5M +$17M +781,620 +73%
Viking Global Investors
9
Viking Global Investors
Connecticut
$41.9M – – –
VA
10
VR Adviser
New York
$33.9M – – –
Citadel Advisors
11
Citadel Advisors
Florida
$26.6M -$3.19M -146,614 -11%
DM
12
Deerfield Management
New York
$23.7M +$185K +8,508 +0.8%
FCMV
13
Foresite Capital Management V
California
$20.1M – – –
NHAS
14
Novo Holdings A/S
Denmark
$11.5M +$4.32M +198,528 +66%
HMC
15
Harvard Management Company
Massachusetts
$11.5M – – –
Morgan Stanley
16
Morgan Stanley
New York
$9.27M +$6.88M +315,822 +363%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$7.76M +$2.18M +99,973 +42%
RSCM
18
Rock Springs Capital Management
Maryland
$7.67M +$30.5K +1,400 +0.4%
State Street
19
State Street
Massachusetts
$7.66M +$2.08M +95,445 +40%
Federated Hermes
20
Federated Hermes
Pennsylvania
$7.09M – – –
PHS
21
PFM Health Sciences
California
$6.08M – – –
WP
22
Woodline Partners
California
$5.99M – – –
Northern Trust
23
Northern Trust
Illinois
$4.87M +$1.65M +75,840 +56%
EC
24
EcoR1 Capital
California
$4.03M +$3.27M +150,000 +600%
American Century Companies
25
American Century Companies
Missouri
$4M +$1.55K +71 +0%
1
2 3 4

KNTE Hedge Fund Activity: Q3 2021 in Review

73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2021, worth a combined $905M — up 1.6% from $891M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KNTE positions and 6 closed out — a net gain of 11 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Boxer Capital, adding an estimated $17M. The largest seller was Logos Global Management, cutting an estimated $26.9M.

  • 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2021, up from 62 in Q2 2021.
  • Funds reported $905M of Kinnate Biopharma Inc. Common Stock stock for Q3 2021, up 1.6% quarter-over-quarter.
  • 17 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of +11 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2021 was Boxer Capital, an estimated $17M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2021 was Logos Global Management, an estimated $26.9M sold.

Based on aggregated 13F filings for Q3 2021.